KIT and gastrointestinal stromal tumor: On the basis of clinical evidence, primarily in GIST, AML and systemic mastocytosis, KIT-activating alterations are associated with sensitivity to KIT tyrosine kinase inhibitors (TKIs) including imatinib, sunitinib, sorafenib, dasatinib, nilotinib, ponatinib, midostaurin and avapritinib [63,64,65].